Difuran-substituted quinoxalines as a novel class of PI3Kα H1047R mutant inhibitors: Synthesis, biological evaluation and structure-activity relationship
作者:Ning Zhang、Zhimei Yu、Xiaohong Yang、Yan Zhou、Qing Tang、Ping Hu、Jia Wang、Shao-Lin Zhang、Ming-Wei Wang、Yun He
DOI:10.1016/j.ejmech.2018.07.061
日期:2018.9
of 0.137 μM, over 500-fold more potent than Hit-01. Western blotting analysis suggested that 7b could decrease the phosphorylation level of p-AKT, another proof that 7b inhibited PI3Kα H1047R function. Cell viability assay revealed that 7b inhibited HCT116 cancer cell growth with an IC50 value of 11.23 μM. In addition, 7b was found to arrest cell cycle at G1 phase and induce cell apoptosis via up-regulation
磷脂酰肌醇3-激酶α(PI3Kα)是人类癌症中最常见的突变激酶,使其成为有吸引力的癌症治疗靶标。我们 通过高通量筛选活动鉴定了结构新颖的PI3KαH1047R突变抑制剂Hit-01(EC 50 = 76.0μM )。化学优化使我们能够发现化合物7b,该化合物强烈抑制PI3KαH1047R突变体,其EC 50值为0.137μM ,效力比Hit-01高500倍以上。Western印迹分析表明7b可以降低p -AKT的磷酸化水平,这又证明7b抑制了PI3KαH1047R的功能。细胞生存力测定显示7b抑制HCT116癌细胞的生长,IC 50值为11.23μM。此外,发现7b可以通过上调caspase-3,caspase-8和caspase-9蛋白表达来阻止G1期细胞周期并诱导细胞凋亡。总的来说,所有这些数据表明7b可能是开发结构新颖的PI3Kα抑制剂的有希望的先导。